Source: Annual Congress 2012 - Diffuse parenchymal lung disease: clinical profiles and collagen vascular disease
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
J. Streitzig, Z. Weiszhar, C. Balogh, A. Bikov, K. Vincze, L. Tamasi, I. Horvath, V. Muller (Budapest, Hungary). Systemic lupus erythematosus (SLE): Cyto- and chemokines as possible serum markers for pulmonary involvement?. Eur Respir J 2012; 40: Suppl. 56, 719

Member's Comments

No comment yet.

Related content which might interest you: Examining pulmonary function measures in patients with systemic lupus erythematosus (SLE) Source: Virtual Congress 2020 – Rare lung diseases and lung manifestations of extrapulmonary diseases Year: 2020 Lung involvement in systemic lupus erythematosus (SLE) - our own experience Source: Eur Respir J 2002; 20: Suppl. 38, 60s Year: 2002 Pulmonary hypertension in systemic sclerosis and systemic lupus erythematosus Source: Eur Respir Rev 2011; 20: 277-286 Year: 2011 Lung abnormalities in patients with systemic lupus erythematosus Source: Eur Respir J 2001; 18: Suppl. 33, 225s Year: 2001 On diagnostics of pneumonitis in patients with lupus erythematosus (LE) Source: Eur Respir J 2005; 26: Suppl. 49, 31s Year: 2005 Systemic lupus erythematosus-associated PAH: is targeting inflammation the key to success? Source: Eur Respir Rev 2011; 20: 218-219 Year: 2011 Pulmonary involvement in systemic lupus erythematosus, Sjögren syndrome and mixed connective tissue disease Source: Eur Respir Monogr 2019; 86: 106-123 Year: 2019 Pulmonary manifestations in systemic lupus erythematosus (SLE) and changes in peripheral blood CD4+ lymphocyte subsets Source: Annual Congress 2010 - Clinical aspects of asthma and allergic respiratory diseases Year: 2010 Management and prognosis of respiratory manifestations revealing systemic lupus erythematosus Source: Annual Congress 2007 - Miscellaneous interstitial lung diseases related to systemic and other diseases Year: 2007 Management of PAH associated with systemic lupus erythematosus (SLE) or mixed connective tissue disease (MCTD): immunosuppressive therapy (IT) alone or combined with PAH specific therapies? Source: Eur Respir J 2007; 30: Suppl. 51, 344s Year: 2007 Interstitial lung disease associated with systemic lupus erythematosus : a monocentric study of 23 cases. Source: Virtual Congress 2021 – Exercise tolerance, supportive care and more in non-pulmonary fibrosis interstitial lung diseases Year: 2021 Endothelium dysfunction in systemic lupus erythematosus patients with pulmonary hypertension Source: Annual Congress 2011 - Clinical features of pulmonary hypertension Year: 2011 Pulmonary arterial hypertension and systemic lupus erythematosus Source: Annual Congress 2009 - Pulmonary circulation I Year: 2009 Cardio-pulmonary exercise testing in systemic lupus erythematosus patients Source: Eur Respir J 2005; 26: Suppl. 49, 350s Year: 2005 The profile of lung scintigraphy in systemic lupus erythematosus with chronic pulmonary embolism:a cross-section Source: Virtual Congress 2020 – Epidemiology, diagnosis and management of pulmonary embolism Year: 2020 A functionally improved case of obstructive impairment caused by systemic lupus erythematosus Source: Breathe, 17 (2) 200288; 10.1183/20734735.0288-2020 Year: 2021 Shrinking lung syndrome (SLS) associated with systemic lupus erythematosus (SLE): A series of cases in a university hospital. Source: International Congress 2019 – Rare and ultra-rare diseases and the lungs: updates and new perspectives Year: 2019 Effectiveness of ²Korargin² in the therapy of pulmonary arterial hypertension in patients with systemic lupus erythematosus Source: Annual Congress 2011 - Treatment of pulmonary hypertension Year: 2011 Pulmonary hypertension in systemic lupus erythematosus – a retrospective analysis Source: Annual Congress 2009 - Pulmonary arterial hypertension Year: 2009 Immunosuppression in systemic lupus erythematosus associated pulmonary arterial hypertension (SLE-APAH): Improvement in exercise and functional capacity Source: Annual Congress 2011 - Treatment of pulmonary hypertension Year: 2011